Merit Medical Systems

MMSI

Market cap $3.76B

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

SOUTH JORDAN, Utah, May 19, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that shareholders elected Scott R. Ward to the company's Board of Directors at Merit's annual meeting of shareholders.

Merit Medical Systems, Inc. (MMSI) Presents at Bank of America Global Healthcare Conference 2026 Transcript

SOUTH JORDAN, Utah, May 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that Merit management will participate in the Bank of America 2026 Health Care Conference, to be held in Las Vegas, Nevada, May 12-14, 2026.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026.

MMSI tops Q1 estimates with 9% EPS growth and 7% revenue rise, while lifting its 2026 sales outlook amid steady segment and geographic gains.

Merit Medical Systems, Inc. (MMSI) Q1 2026 Earnings Call Transcript

Merit Medical (MMSI) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.86 per share a year ago.

Financial Highlights† Reported revenue of $381.9 million, up 7% Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively Constant currency revenue, organic* increased 4%, excluding revenue from divested product line GAAP operating margin of 11.6%, compared to 11.5% in prior year period Non-GAAP operating margin* of 19.7%, compared to 19.3% in prior year period GAAP EPS $0.68, up 39% Non-GAAP EPS* $0.94, up 9% Free cash flow* generation of $24.7 million, up 26% Business Developments On February 17, 2026, Merit sold certain assets related to the DualCap® product line to Health Line International Corporation for a purchase price of $28 million, of which $25.5 million was paid in cash at closing On April 1, 2026, Merit acquired View Point Medical, Inc., manufacturer of the OneMark® Detection Imaging System and OneMark Tissue Markers, for $140 million, of which $90 million was paid in cash at closing Beginning in the first quarter of 2026, Merit reorganized the presentation of revenue into two product categories – Foundational and Therapeutic - to better reflect the clinical uses of our diverse portfolio of products** † Comparisons above are calculated for the current quarter compared with the first quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.